Aims To compare the efficacy and safety of two titration algorithms for insulin degludec/insulin aspart (IDegAsp) administered once daily with metformin in participants with insulin-na€ ıve Type 2 diabetes mellitus.
Introduction
People with diabetes who require intensified (prandial and basal) insulin therapy can find it challenging to manage separate basal and bolus injections, which may become a barrier to adherence to treatment [1] . Regular self-monitored plasma glucose (SMPG) allows people with diabetes to adjust their insulin dose as necessary according to titration algorithms in order to maintain appropriate glycaemic control. However, SMPG can be perceived as burdensome and incurs significant healthcare costs [2, 3] . In order to improve adherence to insulin treatments, and to reduce the burden associated with multidose insulin regimens, novel insulins designed to have a longer duration of action and lower variability with reduced episodes of hypoglycaemia may allow for a clinically simplified treatment regimen for physicians and people with diabetes alike [4] . Insulin degludec/insulin aspart (IDegAsp) is a soluble insulin coformulation of insulin degludec (IDeg, 70%), a basal insulin with a stable, ultra-long duration of action, combined with insulin aspart (IAsp, 30%), a rapid-acting bolus insulin [5, 6] , in a single injection. IDegAsp can be administered once or twice daily with main meal(s). The aim of this study (BOOST â : SIMPLE USE) was to compare the efficacy and safety of two self-titration algorithms (Simple -self-titration performed twice weekly with 3-4 days between titrations; and Stepwise -self-titration performed once weekly) for IDegAsp administered once daily with a main meal plus metformin in participants with insulin-na€ ıve Type 2 diabetes mellitus, inadequately controlled on oral anti-diabetic drugs alone. This was done by comparing the difference in change from baseline in HbA 1c after 26 weeks of treatment between IDegAsp once daily using the Simple titration algorithm + metformin and IDegAsp once daily using the Stepwise algorithm + metformin to a non-inferiority limit of 0.4% (≤ 4 mmol/mol).
Participants and methods
The study (BOOST â : SIMPLE USE) was a 26-week, Simple , participants titrated their insulin dose twice weekly using 2-U increments or decrements based on a single pre-breakfast SMPG measurement on the day of titration (Table S1 ). For IDegAsp Stepwise , participants titrated their insulin dose once weekly using increments or decrements of 2-8 U based on the lowest of three consecutive pre-breakfast SMPG readings (2 days before, and on the day of titration) (Table S2 ). In both groups, the IDegAsp dose was titrated to achieve pre-breakfast plasma glucose values of 4.0-5.0 mmol/l (71-90 mg/dl). IDegAsp was administered once daily with a main meal at a starting dose of 10 U in both titration groups. Any changes in injection schedule were guided by a physician during either a visit or telephone contact. Participants continued on the same dose of metformin; all other oral anti-diabetic drugs were discontinued before the start of the trial.
The primary endpoint was the change in HbA 1c (%) from baseline to after 26 weeks of treatment, using a noninferiority limit of 0.4% (≤ 4 mmol/mol). Secondary efficacy endpoints included change in fasting plasma glucose from baseline, the proportion of participants who achieved HbA 1c targets and 8-point SMPG profiles. Secondary safety endpoints included insulin dose, body weight, adverse events and hypoglycaemic episodes. Confirmed hypoglycaemic episodes included those with a plasma glucose value < 3.1 mmol/l (56 mg/dl) and/or severe hypoglycaemic episodes (in which the participant required assistance). Hypoglycaemic episodes that occurred between 00.01 and 05.59 h (both inclusive) were classified as nocturnal. All endpoints were analysed as detailed in the Supporting Information (statistical analyses).
Results
Of 276 participants, 136 were randomly allocated to the IDegAsp Simple group and 140 to the IDegAsp Stepwise group. Baseline characteristics (Table 1 ) and participant disposition ( Fig. S1 ) were similar in the two groups.
What's new?
The co-formulation, insulin degludec/insulin aspart (IDegAsp), provides basal and mealtime insulin coverage in a single injection.
IDegAsp may be titrated using two titration algorithms, Simple (titrated twice weekly) or Stepwise (titrated once weekly). Both algorithms effectively reduce HbA 1c levels in participants with insulin-na€ ıve Type 2 diabetes, with similar rates of nocturnal hypoglycaemia and no reported severe hypoglycaemic events. IDegAsp Stepwise leads to significantly lower rates of overall confirmed hypoglycaemia compared with IDegAsp Simple .
Optimizing titration may facilitate better disease management by healthcare professionals and people with diabetes. There were no significant differences in the mean reduction in fasting plasma glucose between the two groups [ETD À0.4 mmol/l; 95% CI À0.9, 0.09 (À7.6 mg/dl; 95% CI À16.7, 1.6)] (Fig. 1b) . The statistical analyses of the 8-point SMPG showed no statistically significant differences between groups at any of the measured time points. Similarly, the prandial glucose increment after 26 weeks showed no statistically significant differences between groups at any of the measured time points (Figs S2 and S3) . The mean daily insulin dose was similar in both groups at baseline; however, by Week 26, the mean daily insulin dose was 0.7 U/kg in the IDegAsp Simple group vs. 0.7 U/kg in the IDegAsp Stepwise group (mean dose ratio of 1.11 U/kg) (Fig. 1c) . The observed proportion of participants who achieved the American Diabetes Association-recommended HbA 1c target of < 7% at the end of the trial was 58.1% in the IDegAsp Simple group and 49.3% in the IDegAsp Stepwise group. The proportion of participants who achieved HbA 1c targets of < 53 mmol/mol (< 7.0%) without confirmed hypoglycaemia in the last 12 weeks of the trial was 39.5% for IDegAsp Simple 
Safety
At Week 26, mean increase in body weight from baseline was higher for IDegAsp Simple than for IDegAsp Stepwise , but this was not statistically significant (2.6 and 1.9 kg, respectively; ETD 0.9 kg; 95% CI À0.1, 1.8).
Overall (Table S3) .
Discussion
This 26-week study demonstrated that IDegAsp administered once daily and titrated twice weekly using a simple algorithm effectively improved HbA 1c levels, and was noninferior to IDegAsp once daily titrated once weekly using a stepwise titration algorithm. Effective glycaemic control was achieved according to current treatment guidelines [7] , including achievement of target HbA 1c levels of 52.4 mmol/ mol (6.9%) and 54.7 mmol/mol (7.2%) for IDegAsp Simple and IDegAsp Stepwise , after 26 weeks of treatment, a reduction from 66.9 mmol/mol (8.3%) and 66.6 mmol/mol (8.2%) at baseline for IDegAsp Simple and IDegAsp Stepwise , respectively. Fewer than half of the participants in both arms achieved HbA 1c < 53 mmol/mol (< 7.0%) without confirmed hypoglycaemia during the trial. The reduction in HbA 1c from baseline was similar to that seen in people with Type 2 diabetes mellitus na€ ıve to insulin, where twicedaily IDegAsp was non-inferior in lowering HbA 1c , compared with twice-daily biphasic insulin aspart 30 (BIAsp 30), but was superior in lowering fasting plasma glucose from baseline after 26 weeks, and significantly reduced overall confirmed hypoglycaemia [8] . This was also consistent with recent reports in Japanese people with Type 2 diabetes mellitus, demonstrating the superiority of IDegAsp once daily in lowering mean HbA 1c vs. insulin glargine (IGlar) [9] . When administered once or twice daily in people with Type 2 diabetes mellitus previously treated with insulin, IDegAsp demonstrated non-inferiority to BIAsp 30 in lowering HbA 1c from baseline at 26 weeks, with the proportion of participants achieving HbA 1c targets of < 53 mmol/mol (< 7.0%) being 50.4% in the IDegAsp group and 48.6% in the BIAsp 30 group [10]. The odds of achieving an HbA 1c target of < 53 mmol/mol (< 7.0%) without hypoglycaemic episodes during the last 12 weeks of the study were higher for IDegAsp (21% of patients) than for BIAsp 30 (14% of participants) [10] .
Given that participants entering the trial were insulinna€ ıve, the percentage of participants with overall confirmed hypoglycaemia observed in both titration groups was not unexpected (IDegAsp Stepwise 38.6% vs. IDegAsp Simple 46.3%). A similar number has been observed in a previous trial in participants with insulin-na€ ıve Type 2 diabetes mellitus treated with IDegAsp once daily, where the proportion of participants reporting at least one confirmed hypoglycaemia episode during the treatment period was 44% (with both IDegAsp and IGlar) [9] . Notably, however, no participants experienced severe hypoglycaemia in this trial. Together, these findings highlight the effectiveness and safety of treatment with IDegAsp once daily in people with insulinna€ ıve Type 2 diabetes mellitus.
The rate of confirmed hypoglycaemia was numerically lower for IDegAsp Simple (3.3 events/PYE; 46.3% of participants) vs. IDegAsp Stepwise (2.1 events/PYE; 38.6% of participants). This reduction with IDegAsp once daily was previously reported in the aforementioned trial in Japanese people with Type 2 diabetes mellitus in which IDegAsp once-daily treatment was associated with numerically lower rates of overall confirmed hypoglycaemia vs. IGlar (IDegAsp: 1.9 events/PYE vs. IGlar 2.7 events/PYE) [9] . As mentioned above, in a population with uncontrolled Type 2 diabetes mellitus previously treated with once-or twice-daily insulin, IDegAsp administration (twice daily) reduced confirmed hypoglycaemia vs. BIAsp 30 [9.7 vs. 14.0 episodes/PYE for IDegAsp and BIAsp 30 groups, respectively; ERR 0.7 (95% CI 0.5-0.9),
The more conservative nature of the Stepwise algorithm may explain the lower rates of overall confirmed hypoglycaemia and the lower mean daily insulin dose in the Stepwise arm. According to the Simple algorithm, dose adjustment was based on a single SMPG measurement rather than the lowest of three measurements required by the Stepwise algorithm, meaning that there was always a possibility that dose adjustments in the Simple arm were made based on a random high SMPG value.
The percentage of participants with adverse events in both groups was 53.7% for the IDegAsp Simple group vs. 63.6% for the IDegAsp Stepwise group. IDegAsp was well tolerated in both titration groups and no safety issues were identified during the trial.
These results provide insights into two possible titration methods that may be suitable for use with IDegAsp. For people with diabetes who are inadequately controlled on oral anti-diabetic drugs alone, and who require transition to insulin therapy, these methods potentially offer physicians the option to administer a personalized insulin titration regimen that is tailored to individual needs.
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